Clinical Trials Insight: 700026815
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2010
At a glance
- Drugs Danoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors InterMune
- 01 Oct 2008 Status changed from active, no longer recruiting to completed.
- 24 Sep 2008 Results from this study will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 31 - Nov. 4, in San Francisco, California.
- 29 May 2008 It is expected that results from all dose cohorts will be submitted for possible presentation at this years Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) held in Oct-Nov, reported in an InterMune media release.